The MIT Corporation, the Institute's board of trustees, has elected 10 full-term members and 2 life members, who will serve five-year terms. Corporation Chair Mark P. Gorenberg announced the election results today. The new full-term members are:
- Kate A. Bergeron, Vice President of Hardware Engineering at Apple, Inc., joined Apple in 2002 and has been Vice President since 2014.
- Elizabeth Choe, Director of AI Strategy for Translational Medicine at AstraZeneca, oversees the deployment of biomedical deep-learning models for cancer drug development.
- Kevin B. Churchwell, CEO of Boston Children's Hospital, dedicated to advancing child health through clinical care and research.
- Stephen P. DeFalco, Executive Chair of Creation Technologies, previously served as Chairman and CEO.
- Bennett W. Golub, Co-founder and Senior Advisor at BlackRock, formerly Chief Risk Officer.
- Pearl S. Huang, CEO and President of Dunad Therapeutics, with extensive experience in biotech and pharmaceuticals.
- Steve Isakowitz, former CEO and President of the Aerospace Corporation, has advanced U.S. leadership in space.
- Adrianna C. Ma, Operating Partner at Index Ventures, oversees operations and fundraising.
- Pamela Melroy, President and Managing Partner of Melroy and Hollett Technology Partners, was previously NASA Deputy Administrator.
- Alex Morcos, Co-founder of Chaincode Labs, focusing on Bitcoin open-source software and education.
The two new life members are:
- Eran Broshy, former CEO and Chair of Syneos Health, with over 35 years of experience in healthcare.
- Ray A. Rothrock, Partner Emeritus at Venrock, focusing on early-stage investments in IT and clean energy.
As of July 1, 2026, the Corporation will consist of 75 distinguished leaders in education, science, engineering, and industry, with 22 life members and 8 ex officio members.
Blogger's Review: The new members of the MIT Corporation not only have significant achievements in their respective fields but also represent a new trend at the intersection of education and technology. Their inclusion is expected to inject fresh energy into MIT's future development, particularly in the applications of AI and biomedicine, fostering more innovations.